646071-39-8

Basic information

• Product Name: Benzaldehyde, 3-methoxy-4-[2-(4-methyl-1-piperazinyl)ethoxy]-
• CAS NO: 646071-39-8
• Molecular Formula: C15H22N2O3
• Molecular Weight: 278.351
• Mol File: 646071-39-8.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Benzaldehyde, 3-methoxy-4-[2-(4-methyl-1-piperazinyl)ethoxy]-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzaldehyde, 3-methoxy-4-[2-(4-methyl-1-piperazinyl)ethoxy]-(646071-39-8)
• EPA Substance Registry System: Benzaldehyde, 3-methoxy-4-[2-(4-methyl-1-piperazinyl)ethoxy]-(646071-39-8)

Safety Data

• Hazardous Substances Data: 646071-39-8(Hazardous Substances Data)

Upstream product

• 109-01-3 1-methyl-piperazine 
• 17792-74-4 4-methylbenzenesulfonic acid [(4-formyl-2-methoxyphenoxy)ethyl] ester 
• 64673-04-7 3-methoxy-4-(2-hydroxyethoxy)benzaldehyde 
• 99070-23-2 4-(2-bromo-ethoxy)-3-methoxy-benzaldehyde 
• 121-33-5 vanillin 
• 5464-12-0 2-(4-methylpiperazinyl)ethanol 

Relevant articles and documents

3 - (4 - Methylpiperidine -1 -yl) -3 -benzyl urea compound and the like. Preparation method and application

3 - (4 - Methylpiperi -1 -yl) -3 -benzyl urea compounds and analogs thereof, and a preparation method and application thereof belong to the technical field of medicines, and particularly relates to preparation of 3 - (4 - methylpiperi -1-yl) -3 - benzyl u

3-PHENYL ANALOGS OF TOXOFLAVINE AS KINASE INHIBITORS

The present invention concerns the compounds of formula (I) the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein n represents an integer being 0, 1 or 2; m represents an integer being 0 or 1; R1 represents C I -4alkyl; R2 represents C I -4alkyl; R3 represents CI-4alkyl; or R2 and R3 taken together with the carbon atom to which they are attached form a C3-8cycloalkyl or Het1 wherein said C3-8cycloalkyl or Het1 each independently may optionally be substituted with C1-4alkyloxycarbonyl; R4 represents halo or C I -4alkyloxy; R5 represents C 1-4alkyloxycarbonyl, -O-(mono- or di(C1-4alkyl)aminosulfonyl), CI-4alkyl substituted with one or where possible more substituent being selected from Het3 or NR6R7, C1-4alkyloxy substituted with one or where possible more substituents being selected from amino, Het4or NR8R9; R6 and R7are each independently selected from hydrogen, C I-4alkyl, C I-4alkyloxyC1-4alkyl, -Het5 or CI-4alkyl substituted with one or where possible more substituents being selected from hydroxy, or Het5; R8 and R9 are each independently selected from hydrogen, C,1-4alkyl, -Het7 or mono- or di(C 1-4alkyl)aminosulphonyl; Het3represents a heterocycle selected from piperidinyl, or piperazinyl wherein said monocyclic heterocycles each independently may optionally be substituted with one, or where possible two or three substituents each independently selected from hydroxy, aminosulfonyl, amino, mono-or di(C 1-4 alkyl)aminosulfonyl, hydroxyC 1-4alkyloxyC1-4alkyl or C1-4alkyloxy; Het4represents a heterocycle selected from morpholinyl, piperidinyl or piperazinyl wherein said monocyclic heterocycles each independently may optionally be substituted with one, or where possible two or three substituents each independently selected from C1-4alkyl, C1-4alkyloxycarbonyl or mono- or di(C1-4alkyl)aminosulfonyl; Het5 represents a heterocycle selected from pyridinyl or piperidinyl wherein said monocyclic heterocycles each independently may optionally be substituted with one, or where possible two or three substituents each independently selected from aminosulfonyl, or mono- or di(Cl-4alkyl)aminosulfonyl; Het7 represents piperidinyl.